Patents by Inventor Anke Baum

Anke Baum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210038602
    Abstract: The present invention relates to the use of volasertib, or a pharmaceutically acceptable salt thereof or a hydrate thereof, in combination with a BET inhibitor, or a pharmaceutically acceptable salt thereof or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML).
    Type: Application
    Filed: January 24, 2019
    Publication date: February 11, 2021
    Inventors: Ulrike TONTSCH-GRUNT, Anke BAUM, Dorothea Ingrid RUDOLPH
  • Publication number: 20210009588
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Publication number: 20190358230
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 28, 2019
    Inventors: Michael GMACHL, Michael SANDERSON, Dirk KESSLER, Christiane KOFINK, Matthew Russell NETHERTON, Juergen RAMHARTER, Tobias WUNBERG, Marco HOFMANN, Fabio SAVARESE, Anke BAUM, Dorothea RUDOLPH
  • Publication number: 20190194192
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Publication number: 20180360834
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: December 19, 2017
    Publication date: December 20, 2018
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Publication number: 20180086744
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I) wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 29, 2018
    Inventors: Flavio SOLCA, Andree AMELSBERG, Gerd STEHLE, Jacobus C.A. VAN MEEL, Anke BAUM
  • Publication number: 20170112835
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: October 31, 2016
    Publication date: April 27, 2017
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Patent number: 9539258
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 10, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
  • Publication number: 20150272954
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Application
    Filed: June 15, 2015
    Publication date: October 1, 2015
    Inventors: Flavio SOLCA, Andree AMELSBERG, Jacobus C.A. van MEEL, Anke BAUM, Gerd STEHLE
  • Publication number: 20150265610
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Patent number: 9089571
    Abstract: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: July 28, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Flavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
  • Patent number: 8992915
    Abstract: The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and ICE. The combination of CD37 antibodies and ICE is shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: March 31, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Anke Baum, Charlotte Astrid Russell
  • Publication number: 20140199298
    Abstract: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I) wherein the groups Ra to Rd have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 17, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Flavio SOLCA, Andree AMELSBERG, Gerd STEHLE, Jacobus C.A. VAN MEEL, Anke BAUM
  • Patent number: 8722694
    Abstract: The present invention relates to bicyclic heterocycles of general formula wherein Ra to Rc, A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: May 13, 2014
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Thomas Metz, Flavio Solca, Birgit Jung, Anke Baum
  • Publication number: 20140093498
    Abstract: The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/DII4 binders and anti-VEGF-R agents for use in treating diseases like cancer and ocular diseases.
    Type: Application
    Filed: September 26, 2013
    Publication date: April 3, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas GSCHWIND, Anke BAUM
  • Publication number: 20140093499
    Abstract: The present invention relates to pharmaceutical combinations comprising dual Angiopoietin-2/Dll4 binders and anti-VEGF agents for use in treating diseases like cancer and ocular diseases.
    Type: Application
    Filed: September 26, 2013
    Publication date: April 3, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas GSCHWIND, Anke BAUM
  • Publication number: 20140057898
    Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Martin Friedrich STEFANIC, Frank HILBERG, Gerd MUNZERT, Flavio SOLCA, Anke BAUM, Jacobus C.A. van MEEL
  • Publication number: 20140018372
    Abstract: A crystalline form of 3-{3-[1-(4-Dimethylaminomethyl-phenylamino)-1-phenyl-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-6-yl}-propynoic acid ethylamide.
    Type: Application
    Filed: July 9, 2013
    Publication date: January 16, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Gerd-Michael MAIER, Anke BAUM, Bodo BETZEMEIER, Manuel HENRY, Rolf HERTER, Ulrich REISER, Patrizia SINI, Dirk WEBER, Ulrike WERTHMANN, Stephan Karl ZAHN
  • Patent number: 8591895
    Abstract: Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: November 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerd Munzert, Martin Steegmaier, Anke Baum
  • Publication number: 20130309225
    Abstract: The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and ICE. The combination of CD37 antibodies and ICE is shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.
    Type: Application
    Filed: May 15, 2013
    Publication date: November 21, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Karl-Heinz HEIDER, Anke BAUM, Charlotte Astrid RUSSELL